A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...

A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...

and visible cramps or twitching from lower motor neuron degeneration Bulbar involvement (caused by damaged nerve cells in part of the brain), showing up as difficulty speaking (dysarthria), difficulty ...

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, ...

ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

They repeated the experiment in cells taken from people with ... a high intake of omega-3 fatty acids have a lower risk of developing motor neuron disease. “Our study adds a deeper understanding ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

Over nearly 7 years, the autologous hematopoietic stem-cell-based gene therapy led to lower risk of severe motor impairment or death compared with a no-treatment natural history cohort in three ...

Somatic yoga borrows principles from somatic therapy to help people form a bridge between their body and mind. Learn about ...